Filed: May 08, 2015
Latest Update: Mar. 02, 2020
Summary: NOT RECOMMENDED FOR FULL-TEXT PUBLICATION File Name: 15a0347n.06 No. 14-1637 FILED May 08, 2015 DEBORAH S. HUNT, Clerk UNITED STATES COURT OF APPEALS FOR THE SIXTH CIRCUIT UNITED STATES OF AMERICA, ) ) Plaintiff-Appellee, ) ) ON APPEAL FROM THE v. ) UNITED STATES DISTRICT ) COURT FOR THE SCOTT BERNARD WILL ) WESTERN DISTRICT OF Defendant-Appellant. ) MICHIGAN ) ) ) BEFORE: DAUGHTREY, GIBBONS, and GRIFFIN; Circuit Judges. JULIA SMITH GIBBONS, Circuit Judge. Following a trial in the United States
Summary: NOT RECOMMENDED FOR FULL-TEXT PUBLICATION File Name: 15a0347n.06 No. 14-1637 FILED May 08, 2015 DEBORAH S. HUNT, Clerk UNITED STATES COURT OF APPEALS FOR THE SIXTH CIRCUIT UNITED STATES OF AMERICA, ) ) Plaintiff-Appellee, ) ) ON APPEAL FROM THE v. ) UNITED STATES DISTRICT ) COURT FOR THE SCOTT BERNARD WILL ) WESTERN DISTRICT OF Defendant-Appellant. ) MICHIGAN ) ) ) BEFORE: DAUGHTREY, GIBBONS, and GRIFFIN; Circuit Judges. JULIA SMITH GIBBONS, Circuit Judge. Following a trial in the United States D..
More
NOT RECOMMENDED FOR FULL-TEXT PUBLICATION
File Name: 15a0347n.06
No. 14-1637 FILED
May 08, 2015
DEBORAH S. HUNT, Clerk
UNITED STATES COURT OF APPEALS
FOR THE SIXTH CIRCUIT
UNITED STATES OF AMERICA, )
)
Plaintiff-Appellee, )
)
ON APPEAL FROM THE
v. )
UNITED STATES DISTRICT
)
COURT FOR THE
SCOTT BERNARD WILL )
WESTERN DISTRICT OF
Defendant-Appellant. )
MICHIGAN
)
)
)
BEFORE: DAUGHTREY, GIBBONS, and GRIFFIN; Circuit Judges.
JULIA SMITH GIBBONS, Circuit Judge. Following a trial in the United States
District Court for the Western District of Michigan, a jury found Defendant-Appellant Scott Will
guilty of distributing, as well as conspiring to distribute, controlled substance analogues. On
appeal, Will argues that the district court erred in admitting evidence of Will’s previous
possession of a controlled substance analogue and erred in deeming his prior possession relevant
conduct for the purposes of sentencing. For the following reasons, we affirm Will’s conviction.
I.
On three separate occasions in 2013, an undercover officer both video-recorded and
audio-recorded Will selling controlled substance analogues—alpha-pyrrolidinopentiophenone
(alpha-PVP) and pentylone—to the officer. As a result, on May 29, 2013, Will and others were
indicted by a grand jury on one count of conspiring to distribute controlled substance analogues,
three counts of distributing controlled substance analogues for human consumption, and one
United States v. Will
14-1637
count of possessing a controlled substance analogue with intent to distribute, in violation of 21
U.S.C. §§ 846, 841(a)(1), 813.
Before trial, Will filed a motion in limine to exclude evidence of Will’s prior distribution
of methylenedioxypyrovalerone (“MDPV”) in May 2011. Specifically, in May of 2011, police
officers were dispatched to a hotel to investigate suspected drug activity. Once there, the officers
encountered Will and found 102 small bottles containing an off-white powder labeled “not for
human consumption” in Will’s bag. The officers also discovered numerous syringes and metal
spoons in Will’s room. A test revealed that the white powder was MDPV, a controlled substance
analogue. Soon after, in October of 2011, MDPV was scheduled as a controlled substance. As a
result of this incident, Will pled guilty to possession of a controlled substance analogue in state
court and served nearly six months in jail. In lieu of adding this prior conviction to Will’s
criminal history points, the government deemed it relevant conduct and used the MDPV from the
May 2011 incident to calculate Will’s base offense level. The court held its ruling in abeyance
until trial.
A four-day jury trial began on December 9, 2013. On the last day of the trial, the court
determined that the government was permitted to admit evidence of Will’s May 2011 conduct.
On December 12, 2013, the jury found Will guilty of all counts. Will timely appealed.
II.
Will argues that the district court erred in admitting evidence of his 2011 MDPV
possession because it was unfairly prejudicial. Specifically, he contends that because MDVP
was not yet scheduled as a controlled substance at the time of his 2011 possession, the probative
value of such evidence was far outweighed by the prejudicial impact on the jury. The
government counters that the admitted evidence was highly probative and therefore outweighed
2
United States v. Will
14-1637
any unfair prejudice because it demonstrated Will’s intent to distribute, see United States v.
Ayoub, 498 F.3d 532, 548 (6th Cir. 2007) (“[P]rior drug-distribution evidence is admissible to
show intent to distribute.”), and the “not for human consumption” label shows that Will had first-
hand knowledge of the physiological effects of MDPV, now a controlled substance, for which
alpha-PVP is the closest analogue.1
We review a district court’s evidentiary rulings for abuse of discretion. See United States
v. Allen, 619 F.3d 518, 523 (6th Cir. 2010). Pursuant to Federal Rule of Evidence 404(b),
evidence of a crime or wrong is not admissible to prove a person’s character but is admissible to
prove a defendant’s knowledge. Evidence of prior convictions or bad acts may also be
admissible under Rule 404(b) for the purposes of proving intent, especially where a defendant is
charged with an offense necessitating specific intent, such as conspiracy to possess and distribute
drugs. United States v. Myers,
102 F.3d 227, 234 (6th Cir. 1996). A district court determines the
admissibility of evidence under Rule 404(b) by applying a three-step process:
First, the district court must decide whether there is sufficient evidence that the
other act in question actually occurred. Second, if so, the district court must
decide whether the evidence of the other act is probative of a material issue other
than character. Third, if the evidence is probative of a material issue other than
character, the district court must decide whether the probative value of the
evidence is substantially outweighed by its potential prejudicial effect.
United States v. Clay, 667 F.3d 689, 693 (6th Cir. 2012) (citations omitted).
Will contends that the district court erred in not excluding the evidence because, under the third
step of the test, the admission of the May 2011 MDPV possession was unfairly prejudicial.
1
The Sixth Circuit has not yet addressed whether § 841(a) has a scienter requirement. The Seventh Circuit has
found that it does: “A defendant must know that the substance at issue has a chemical structure substantially similar
to that of a controlled substance, and he or she must either know that it has similar physiological effects or intend or
represent that it has such effects.” United States v. Turcotte,
405 F.3d 515, 527 (7th Cir. 2005). The Fourth Circuit,
however, has held that the government need only prove that the alleged analogues were substantially similar to a
Schedule I or Schedule II controlled substance. See United States v. McFadden,
753 F.3d 432, 443–44 (4th Cir.
2014), cert. granted,
135 S. Ct. 1039 (2015). To avoid an appeal issue, the government has agreed to apply the
Seventh Circuit’s strict knowledge standard. We therefore examine whether Will knew that alpha-PVP’s
physiological effects were similar to those of MDPV.
3
United States v. Will
14-1637
District courts possess broad discretion in admitting evidence under Rule 404(b). See
United States v. Vance, 871 F.2d 572, 576 (6th Cir. 1989). Moreover, the evidence must be
“unfairly” prejudicial, not merely prejudicial. See United States v. Bonds,
12 F.3d 540, 567 (6th
Cir. 1993). “Unfair prejudice . . . refers to evidence which tends to suggest decision on an
improper basis.”
Id. (emphasis added).
In assessing the issue of unfair prejudice, the district court determined that Will’s 2011
possession of MDPV was not unfairly prejudicial because “the government has the obligation to
prove . . . the elements of all of these offenses, and that includes the intent to distribute an
analogue for human consumption.” This court has specifically held it proper to admit evidence
of other crimes or prior bad acts in cases when used to prove intent to engage in the distribution
of drugs. See Myers, 102 F.3d at 234. The district court also eliminated the potential for unfair
prejudice by providing limiting instructions to the jury following the testimony of the two
officers who discovered the MDPV in Will’s bag. The jury was properly instructed on multiple
occasions to consider Will’s prior conduct only as it related to Will’s intent and knowledge.
Id.
at 233–34 (finding no error in admitting prior bad acts evidence when accompanied by a limiting
instruction as to purpose of the evidence and noting with approval the district court’s repeated
instructions to the jury on consideration of this type of evidence). In light of these facts, we
cannot say the district court abused its discretion.
III.
Will further contends that the district court erred in considering that the MDPV that he
possessed in May of 2011 constituted relevant conduct under the sentencing guidelines. A
district court’s factual findings are reviewed for clear error, while the determination that the
conduct at issue constitutes relevant conduct is reviewed de novo. United States v. Myers,
4
United States v. Will
14-1637
123 F.3d 350, 364 (6th Cir. 1997). Under the clearly-erroneous standard, we will leave the
district court’s factual findings undisturbed unless we are “left with the definite and firm
conviction that a mistake has been committed.” United States v. Darwich,
337 F.3d 645, 664
(6th Cir. 2003) (citations and internal quotation marks omitted).
In Will’s view, because MDPV was not classified as a Schedule I controlled substance
until October of 2011, the MDPV that he possessed prior to that date should not have been added
to the drug quantity attributed to him. The government, on the other hand, contends that even
though MDPV was not a Schedule I controlled substance at the time of Will’s guilty plea, it was
still a controlled substance analogue—making its sale illegal. See 21 U.S.C. § 841(a)(1) (“[I]t
shall be unlawful for any person knowingly or intentionally . . . to manufacture, distribute, or
dispense, or possess with intent to manufacture, distribute, or dispense, a controlled substance.”);
21 U.S.C. § 813 (“A controlled substance analogue shall, to the extent intended for human
consumption, be treated, for the purposes of any Federal law as a controlled substance in
schedule I.” (emphasis added)). Because Will’s distribution of MDPV was illegal, the
government argues, it was properly included as relevant conduct for his 2013 convictions of
distribution and possession of, as well as conspiracy to distribute, controlled substance
analogues.
Prior drug dealings amount to relevant conduct if they constitute a “common scheme or
plan” or are “part of the same course of conduct.” U.S.S.G. § 1B1.3(a)(2). Two or more
offenses represent a “common scheme or plan” if they are “substantially connected to each other
by at least one common factor, such as common victims, common accomplices, common
purpose, or similar modus operandi.” U.S.S.G. § 1B1.3, cmt. n.9(A). Two or more offenses
constitute the “same course of conduct” if they are “sufficiently connected or related to each
5
United States v. Will
14-1637
other as to warrant the conclusion that they are part of a single episode, spree, or ongoing series
of offenses.” Id. at n.9(B).
The undisputed facts support a finding that the nature of the 2011 and 2013 offenses is
substantially similar. Both Will’s 2011 conduct and the instant offenses involved the sale of
controlled substance analogues, as the district court found.2 See United States v. Brown,
332 F.3d 363, 376 (6th Cir. 2003) (upholding a district court’s finding that defendant’s prior
indictment constituted relevant conduct because both the conduct and the underlying offense
involved the same drug). The facts also warrant a finding that Will’s modus operandi was
similar for both the 2011 offense and his 2013 conduct: he generally sold his product from
motels. Moreover, Will’s 2011 conviction served to demonstrate Will’s intent to distribute a
controlled substance analogue for human consumption, as well as the knowledge of the nature of
a controlled substance analogue. For these reasons, the district court did not err in finding Will’s
prior conviction regarding the sale of MDPV relevant conduct. 3 Thus, the district court properly
included the MDPV sold during Will’s relevant conduct–i.e., his May 2011 offense– in its drug
quantity calculation. See U.S.S.G. § 2D1.1, cmt. n.5 (“Types and quantities of drugs not
specified in the count of conviction may be considered in determining offense level”).
IV.
For the reasons stated above, we affirm the district court’s judgment of conviction.
2
In fact, Will’s counsel conceded that MDPV was a controlled substance analogue at the time Will pled
guilty to its possession in 2011.
3
Importantly, the district court did not include Will’s 2011 conviction in calculating his criminal history
category. See United States v. Collins, 188 F.3d 509 (6th Cir. 1999) (unpublished table decision) (acknowledging
that prior offense is not a prior sentence for the purposes of computing a defendant’s criminal history category when
that prior offense is deemed relevant conduct.
6
